Total Body Irradiation without Chemotherapy as Conditioning for an Allogeneic Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia
Table 1
Patient characteristics.
Patient number
Age (years) and gender
Cytogenetics
Timing of diagnosis (days prior to cell infusion)
Treatment #1 and response (days prior to cell infusion)
Treatment #2 and response (days prior to cell infusion)
Treatment #3 and response (days prior to cell infusion)
Relapse (days prior to cell infusion)
Treatment #1 and response (days prior to cell infusion)
Treatment #2 and response (days prior to cell infusion)
1
20, female
46 XX
Day −149
IDAC Refractory Day −146
NOVE Refractory Day −98
FLAG Refractory Day −48
NA
NA
NA
2
25, female
49 XX, +8, +9, +11
Day −92
IDAC Refractory Day −91
NOVE CR Day −57
NA
NA
NA
NA
3
37, female
46 XX
Day −1056
IDAC CR Day −1049
IDAC Continuing CR Day −1003
NA
Day −91
NOVE Refractory Day −83
HiDAC CR Day −38
4
55, female
46 XX, t(9,11)
Day −370
IDAC CR Day −366
IDAC Continuing CR Day −324
HiDAC Continuing CR Day −268
Day −128
NOVE Refractory Day −126
FLAG CR Day −58
IDAC: idarubicin 12 mg/m2 IV daily for three days and cytarabine 200 mg/m2 by continuous IV infusion daily for 7 days; NOVE: mitoxantrone, 10 mg/m2 IV daily for five days, and etoposide 100 mg/m2 IV daily for 5 days; FLAG: fludarabine 30 mg/m2 IV daily for five days, cytarabine 2 g/m2 IV daily for five days, and filgrastim 480 μg sc daily, starting from the first day of chemotherapy until neutrophil count of 1 × 109/L (FLAG); HDAC: cytarabine, 3 g/m2 IV q12h on days 1, 3, and 5.
